Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations
AnaptysBio has completed the spin-off of its biopharma operations into First Tracks Biotherapeutics and will now operate as a royalty management company. The new virtual model focuses on managing financial collaborations related to Jemperli with GSK and imsidolimab with Vanda, aiming for high operational efficiency and returning value to shareholde…